Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided informed consent prior to any study-specific activities/procedures~* Ambulatory postmenopausal women.~* Age 55 years or older~* Screening BMD value equivalent to a T-score less than or equal to -2.5 at the lumbar spine, total hip, or femoral neck.~Exclusion Criteria:~* Administration of osteoporosis treatments or bone active treatments within specific timeframes~* Vitamin D deficiency~* Diseases and conditions that affect bone metabolism (e.g., hypo/hyper-parathyroidism; hypo/hyperthyroidism, unless stable and well-controlled)~* Contraindications to denosumab therapy (e.g., hypocalcemia)

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab CP2 (Type: ACTIVE_COMPARATOR): Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.
- Denosumab CP4 (Type: EXPERIMENTAL): Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).